 The CISPR-CAS system has revolutionized biomedical research by providing novel tools to investigate the non-coding genome and its role in cancer. The CISPR-CAS-based gene editing technology can precisely and permanently target mutations and micro-ionase, which are important regulators of cellular processes. Despite the promise of this technology, there are several challenges associated with developing effective and safe cancer gene editing therapies. These include the need to avoid off-target effects, the potential for introducing additional abnormalities, and the difficulty of delivering the therapeutics to the desired location within the body. To address these challenges, this review discusses various strategies to improve the safety and efficacy of CISPR-CAS-mediated man-a-gene editing. This article was authored by Bash Dhamma Mood Hussain, Muhammad Fati-Razal, Sneer Rasool Abdullah, and others.